FXR inhibitor, Z-GS, showed a favorable therapeutic effect in decreasing FXR/IL-6/IL-6ST/p-STAT3 axis and treating FXRhigh NSCLC metastasis in mouse models in vivo. This evidence concerns the gene IL6 and non-small cell lung carcinoma.